News | January 23, 2025
Neuland Labs board approves Capex of Rs. 342 Cr
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
The company already has the world’s largest capacity for ibuprofen and is now looking at expansion in new molecules as the idea is to actually de-risk the business
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
Subscribe To Our Newsletter & Stay Updated
